Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic
- 1 August 2015
- journal article
- review article
- Published by Elsevier in Current Opinion in Virology
- Vol. 13, 49-54
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Oncolytic PoxvirusesAnnual Review of Virology, 2014
- An Intravenous Stimulus Package for Oncolytic VirotherapyMolecular Therapy, 2011
- Next-Generation Oncolytic Vaccinia Vectors2011
- Immunotherapeutic potential of oncolytic vaccinia virusImmunologic Research, 2011
- Oncolytic vaccinia virus for the treatment of cancerExpert Opinion on Biological Therapy, 2011
- Oncolytic vaccinia virus: a silver bullet?Expert Review of Vaccines, 2010
- Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancerNature Reviews Cancer, 2009
- Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963Journal of Clinical Investigation, 2007
- Recent progress in the battle between oncolytic viruses and tumoursNature Reviews Cancer, 2005
- Replication-selective adenoviruses as oncolytic agentsJournal of Clinical Investigation, 2000